SCHEMBL6286023

SCHEMBL6286023

COc1ccc(-c2nc3ccncc3[nH]2)cc1NC(=S)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
KDM4E B2RXH2 4/20 0.57
HPGD P15428 4/20 0.57
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.49
MAPT P10636 4/20 0.49
LMNA P02545 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PKM P14618 2/20 0.47
HPSE Q9Y251 3/20 0.45
PDE5A O76074 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
AMY1A P0DUB6 1/20 0.42
GAA P10253 1/20 0.41
CDK4 P11802 1/20 0.41
CCNA2 P20248 1/20 0.41
CCND1 P24385 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711323 0.89 KMT2A (0.48) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6288124 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6288128 0.84 KMT2A (0.52) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6285927 0.84 KMT2A (0.52) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6286100 0.83 KMT2A (0.47) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6286947 0.82 KMT2A (0.52) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6286246 0.82 KMT2A (0.49) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6286030 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6288130 0.80 KMT2A (0.47) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6282536 0.79 ALDH1A1 (0.68) ALDH1A1KDM4EHPGDKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B ALDH1A1 522/4885KDM4E 2221/4885HPGD 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.